tirzepatide adolescent obesity trial A Study of in Adolescents With and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) GLP-1 prescribing among teens with

Stick to a consistent schedule and set reminders to avoid missed doses

Based on current clinical evidence, the rough ordering from largest to smallest weight-loss effect is: Tirzepatide highest average weight loss Semaglutide significant weight loss Tesamorelin moderate weight loss, primarily through visceral fat reduction AOD-9604 primarily body composition effects MOTS-c primarily metabolic and energy effects rather than pure weight reduction AOD-9604 and MOTS-c are generally not considered replacements for GLP-1 medications in patients seeking substantial weight reduction

Foundayo is a small-molecule compound, not a peptide (2)

Comparison pricing displayed on the brand's website should be verified in accordance with applicable local consumer protection standards, including EU Omnibus Directive requirements for price transparency

References Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, Koh ZJ, Chew CA, Loo YE, Tai BC, Kim G, So JBY, Kaplan LM, Dixon JB, Shabbir A

The STEP4 study further confirmed the need to continue weekly therapy with semaglutide 2.4 mg in promoting long-term weight loss maintenance in people living with overweight/obesity, showing continued and persistent weight loss compared to participants transitioning to placebo and regaining body weight [150]